We show that Milciclib decreases H460 cell xenograft 18F-FDG consumption, possibly suggesting that decreased tumor 18F-FDG consumption measured by PET in patients could be used as a pharmacodynamic biomarker of CDK7 inhibitors. The gene discussed is CDK7; the disease is neoplasm.